Supplement Absorption With and Without Enhancing Technology
Official title: Effect of Different Supplement Formulations on Nutrient Absorption in Otherwise Healthy Participants: a Randomised, Parallel-group Study With Double-blinded Omega-3 and Single-blinded Vitamin D3
Run by RDC Clinical Pty Ltd · NCT07791797 · Data updated 2026-11-12
This study tests whether vitamin D3 and omega-3 supplements are absorbed better when using absorption-enhancing technology in healthy adults.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | RDC Clinical Pty Ltd Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Fortitude Valley, Queensland) |
| Status | Recruiting |
| Started | August 31, 2026 |
| Main results expected | September 2027 |
| Study ends | September 2027 |
| Registry record updated | September 10, 2026 |
| Trial ID | NCT07791797 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older who are generally healthy, have BMI 18.5–29.9, and are willing to comply with study visits and restrictions.
✕Probably not a fit
Individuals with significant illnesses, unstable medical conditions, active smoking, or recent major diet/exercise changes may not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 4 interventional study compares the absorption of omega-3 and vitamin D3 supplements formulated with an absorption-enhancing technology versus standard formulations in healthy volunteers. Part A includes single-dose omega-3 arms and daily vitamin D3 for 7 days, while Part B tests daily vitamin D3 for 6 weeks. The study measures how well the supplements enter the bloodstream over time using blood samples collected at scheduled visits. Participants must be adults 18 years or older who are generally healthy and willing to comply with study procedures. Lead sponsor is RDC Clinical Pty Ltd, with the study conducted at RDC Clinical in Fortitude Valley, Queensland.
Why it matters
Potential benefit: Participants may experience improved understanding of how to maximize supplement absorption, potentially benefiting future product formulations.
How similar studies have gone: Previous studies in this area have explored absorption-enhancing formulations for nutrients, with mixed results depending on the compound and technology used.
Who can join: the full rules
Show full inclusion / exclusion criteria
Part A: Inclusion Criteria: * Adults 18 years and older * Generally healthy * BMI 18.5-29.9 kg/m2 * Able to provide informed consent * Agree to not participate in another clinical trial while enrolled in this trial * Agree not to change current diet and/or exercise frequency or intensity during entire study period * Participant's ability to participate fully and comply with demands of the study including attendance at all scheduled blood collection time points Exclusion Criteria: * Have a serious illness e.g. mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease or heart conditions * Have an unstable illness e.g. diabetes and thyroid gland dysfunction * Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years * Significant change in diet in the past 1-month (e.g., removal of a food group or calorie restriction) * Active smokers, nicotine use or drug (prescription or illegal substances) abuse * Chronic past and/or current alcohol use (\>21 alcoholic drinks week) * Pregnant or lactating women * Allergic to any of the ingredients in enhanced or standard formula * Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month (excluding RDC Clinical trials) * Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion * Regular use within the past 4 weeks of supplements containing the trial product Part B: The above criteria apply, plus baseline serum 25(OH)D \<20.0 ng/mL (\<50.0 nm/L)
Where it's running
-
RDC Clinical
Fortitude Valley, Queensland, Australia Recruiting
Study contacts
- Principal investigator: David Briskey — RDC Clinical
- Study coordinator: David Briskey
- Email: research@rdcglobal.com.au
- Phone: +61(0)731024486
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gut microbiome and metabolic health test in healthy adults
This study tests whether TRPTI (oleoylethanolamide) can lower a gut-derived metabolite linked to insulin resistance and improve metabolic health in healthy adults with BMI in the mid range.
-
Sleep and stress relief with lavender, PEA, or OEA supplements
This trial will test whether a daily capsule of lavender oil, PEA, or OEA helps adults with moderate stress who have sleep problems sleep better and feel less stressed.
-
Levagen+ for symptoms of diabetic peripheral neuropathy
This study will try Levagen+, a daily supplement, to see if it reduces nerve pain and other symptoms in adults with diabetic peripheral neuropathy compared with a placebo.
-
How two microalgal omega-3 formulations compare to fish oil and placebo for absorption in healthy adults
This study tests whether two microalgal omega-3 formulations are absorbed as well as fish oil or a placebo in healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.